Search Results for:
-
Other News To Note
Covidien expects to complete the distribution of Mallinckrodt ordinary shares after the close of trading on the New York Stock Exchange on June 28BioWorld International | Wednesday, June 19, 2013 -
Other News To Note
Covidien expects to complete the distribution of Mallinckrodt ordinary shares after the close of trading on the New York Stock Exchange on June 28BioWorld Today | Monday, June 17, 2013 -
Public Financing Of Biotechnology: May 2013
NYSE = New York Stock Exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering priceBioWorld Insight | Monday, June 10, 2013 -
Other News To Note
CorMedix Inc., of Bridgewater, N.J., received a notice from the New York Stock Exchange that CorMedix made reasonable demonstration of its ability to regain compliance with the exchange's rules, and CorMedix's listing will continue through Oct. 20BioWorld Today | Tuesday, June 4, 2013 -
Other News To Note
Allon also reported that the Toronto Stock Exchange determined to halt trading of the company's common shares for failure to meet listing requirementsBioWorld Today | Friday, May 31, 2013 -
Pharma: Other News To Note
Perrigo Co., of Allegan, Mich., is transferring the listing of its U.S.-traded common stock to the New York Stock Exchange (NYSE) from NasdaqBioWorld Today | Friday, May 24, 2013 -
Pharma: Other News To Note
Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costsBioWorld Today | Monday, May 20, 2013 -
Ambit Cuts Price, Ups Shares; $65M IPO to Fund Quizartinib
Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc. barely two months ago, Ambit Biosciences Corp. forged ahead with its initial public offering (IPO). The San Diego-based biotech priced about 8.1 million shares at $8 apiece for gross proceeds of about $65 million. The pricing came in lower than Ambit had hoped – it set a $13 to $15 price range earlier this month – but the firm increased the number of shares offered to make up the difference. ProceedsBy Jennifer Boggs | BioWorld Today | Friday, May 17, 2013 -
Other News To Note
The move is intended to improve the firm's capital structure and continue its strategy of listing shares on a U.S.-based stock exchange in the futureBioWorld Today | Friday, May 10, 2013 -
Galapagos Lands $71M from Stoked U.S. Investors
This was on the initiative of the stock exchange and because of the good liquidityBy Nuala Moran | BioWorld International | Wednesday, May 8, 2013 -
Public Financing Of Biotechnology: April 2013
NYSE = New York Stock Exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering priceBioWorld Insight | Monday, May 6, 2013 -
Galapagos Lands $71M from Stoked U.S. Investors
This was on the initiative of the stock exchange and because of the good liquidityBy Nuala Moran | BioWorld Today | Monday, May 6, 2013 -
Proposed $480M OPKO/Prolor Merger Has Law Firms Circling
and reached into Russia by acquiring a 10 percent stake in OAO Pharmsynthez, a Moscow Stock Exchange-listed firmBy Jennifer Boggs | BioWorld Today | Thursday, April 25, 2013 -
Other News To Note
OPKO Health Inc., of Miami, said it acquired about a 10 percent stake in OAO Pharmsynthez, a Russian pharma firm listed on the Moscow Stock ExchangeBioWorld Today | Friday, April 19, 2013 -
Other News To Note
companies listed on a qualified stock exchange in their home country...ProMetic is traded on the Toronto Stock Exchange under the symbol PLIBioWorld Today | Monday, April 15, 2013 -
Durata Pads Coffers Ahead of NDA; Kamada Files for U.S. IPO
But rumors that the firm might make the leap to Nasdaq had been swirling since last fall, and Kamada's shares, currently listed on the Tel Aviv Stock Exchange under "KMDA," have gained 44 percent since Oct. 1By Jennifer Boggs | BioWorld Today | Monday, April 15, 2013 -
Chinese Biopharmas Depart U.S. Markets to Escape Scandal
Both delistings occurred because the stock exchanges said the two Chinese companies no longer met their financial reporting requirements...Chinese companies on the American stock exchanges are still "closer to the trough," despite the U.SBy Larry Schuster | BioWorld International | Wednesday, April 10, 2013 -
Chinese Biopharmas Depart U.S. Markets to Escape Scandal
Both delistings occurred because the stock exchanges said the two Chinese companies no longer met their financial reporting requirements...Chinese companies on the American stock exchanges are still "closer to the trough," despite the U.SBy Larry Schuster | BioWorld Today | Tuesday, April 9, 2013 -
Public Financing Of Biotechnology: March 2013
NYSE = New York Stock ExchangeBioWorld Insight | Monday, April 8, 2013 -
Geron ESC Assets Regenerate at Asterias Biotherapeutics
CEO Thomas Okarma, who ran Geron for more than a decade, is shooting for the New York Stock Exchange, where the company's shares would be listed under the symbol "ASTBy Marie Powers | BioWorld Today | Friday, April 5, 2013
Category
Current Filters
- xStock Exchange
Related Keywords
Categories
- x BioWorld Insight (1573)
- x BioWorld Today (988)
- x BioWorld International (515)
- x State of the Industry Report (196)
- x BioWorld Snapshots (13)
- x Bio Perspectives (11)
- x BioWorld Genomics Review (7)
- x Executive Compensation Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.